Apimeds Pharmaceuticals US, Inc. (APUS)

APUS Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.06	0.41	0.01
Cash & Cash Equivalents	0.06	0.41	0.01
Cash Growth	-	6551.77%	-
Other Current Assets	0.01	0.01	0
Total Current Assets	0.07	0.42	0.01
Total Assets	-	0.42	0.01
Accounts Payable	-	0.12	0.06
Current Debt	-	-	0.26
Other Current Liabilities	0.49	0	0
Total Current Liabilities	0.49	0.12	0.32
Long-Term Debt	-	0.27	0.4
Total Long-Term Liabilities	-	0.27	0.4
Total Liabilities	-	0.39	0.72
Total Debt	0.4	0.27	0.66
Debt Growth	-	-59.56%	-
Retained Earnings	-	-3	-2.22
Shareholders' Equity	-0.71	0.03	-0.71
Net Cash / Debt	-0.34	0.14	-0.65
Working Capital	-0.41	0.3	-0.31

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).